{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:24Z","timestamp":1786119924011,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/wnf.0b013e318219dad0","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T02:39:15Z","timestamp":1304476755000},"page":"101-103","source":"Crossref","is-referenced-by-count":5,"title":["Levodopa Induces Synthesis of Nerve Growth Factor and Growth Hormone in Patients With Parkinson Disease"],"prefix":"10.1097","volume":"34","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Muhlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0969-9961(03)00081-0","article-title":"Denervation and repeated l-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats.","volume":"14","author":"St-Hilaire","year":"2003","journal-title":"Neurobiol Dis"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","article-title":"Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.","volume":"61","author":"Muller","year":"2004","journal-title":"Arch Neurol"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/mds.22137","article-title":"Neuropathy as a potential complication of levodopa use in Parkinson's disease.","volume":"23","author":"Toth","year":"2008","journal-title":"Mov Disord"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.wnf.0000183447.58529.79","article-title":"Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease.","volume":"28","author":"Muller","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neulet.2007.06.008","article-title":"Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.","volume":"422","author":"Muller","year":"2007","journal-title":"Neurosci Lett"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0014-5793(89)81391-2","article-title":"Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells.","volume":"247","author":"Furukawa","year":"1989","journal-title":"FEBS Lett"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.neuro.051508.135620","article-title":"The influence of stress hormones on fear circuitry.","volume":"32","author":"Rodrigues","year":"2009","journal-title":"Annu Rev Neurosci"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002826-200603000-00001","article-title":"Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.","volume":"29","author":"Muller","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.58.2.241","article-title":"Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.","volume":"58","author":"Friess","year":"2001","journal-title":"Arch Neurol"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jnnp.40.2.162","article-title":"Plasma DOPA levels and growth hormone response to levodopa in parkinsonism.","volume":"40","author":"Galea-Debono","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1172\/JCI118516","article-title":"Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.","volume":"97","author":"Jaffe","year":"1996","journal-title":"J Clin Invest"},{"key":"R12-2-20210203","first-page":"155","article-title":"The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson's disease.","volume":"2","author":"Muller","year":"2010","journal-title":"Clinical Medicine Insights: Therapeutics"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0301-0082(00)00014-9","article-title":"Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease.","volume":"63","author":"Murer","year":"2001","journal-title":"Prog Neurobiol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201105000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:30:40Z","timestamp":1786044640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201105000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318219dad0","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}